Coverage
-
May 20, 2026
Federal Trade Commission staffers have signaled that they're near a settlement with UnitedHealth Group Inc.'s OptumRx that would close out the agency's in-house case accusing pharmacy benefit managers of inflating insulin prices through rebate schemes.
18 other articles on this case.
View all »